Literature DB >> 17134722

Beta-blockers reduce the risk of early death in ischemic stroke.

Tomasz Dziedzic1, Agnieszka Slowik, Joanna Pera, Andrzej Szczudlik.   

Abstract

OBJECTIVES: Beta-blockers reduce mortality in patients after myocardial infarction. Experimental studies suggest that beta-blockers have also neuroprotective properties. The aim of this study was to assess if use of beta-blockers is associated with reduced risk of early death in ischemic stroke patients.
MATERIALS AND METHODS: Retrospective data analysis of 841 consecutive patients with acute ischemic stroke admitted to the stroke unit within 24 h after stroke onset.
RESULTS: 10.6% of patients received beta-blockers during hospitalization. Thirty-day case fatality was significantly lower in patients treated with beta-blockers than in those not treated with beta-blockers (6.8% versus 19.0%, P < 0.01). After adjustment for other prognostic factors, the use of beta-blockers was associated with reduced risk of early death (relative hazard 0.37, 95% confidence interval 0.16-0.84) independently of age, stroke severity, fasting glucose, total cholesterol level and pneumonia. When patients who died of cardiovascular causes were excluded from the analysis, the use of beta-blocker was no longer significantly associated with risk of death (P = 0.12).
CONCLUSION: In a retrospective series the use of beta-blockers was associated with reduced risk of early death in patients with ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17134722     DOI: 10.1016/j.jns.2006.10.007

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  28 in total

1.  Ischemic stroke activates hematopoietic bone marrow stem cells.

Authors:  Gabriel Courties; Fanny Herisson; Hendrik B Sager; Timo Heidt; Yuxiang Ye; Ying Wei; Yuan Sun; Nicolas Severe; Partha Dutta; Jennifer Scharff; David T Scadden; Ralph Weissleder; Filip K Swirski; Michael A Moskowitz; Matthias Nahrendorf
Journal:  Circ Res       Date:  2014-10-31       Impact factor: 17.367

2.  Damage control in the nervous system: beware the immune system in spinal cord injury.

Authors:  Phillip Popovich; Dana McTigue
Journal:  Nat Med       Date:  2009-07       Impact factor: 53.440

Review 3.  Impact of Infection on Stroke Morbidity and Outcomes.

Authors:  Chad M Miller; Réza Behrouz
Journal:  Curr Neurol Neurosci Rep       Date:  2016-09       Impact factor: 5.081

4.  Is β-blocker (atenolol) a preferred antihypertensive in acute intracerebral hemorrhage?

Authors:  Jayantee Kalita; Usha Kant Misra; Bishwanath Kumar
Journal:  Neurol Sci       Date:  2012-10-09       Impact factor: 3.307

Review 5.  The Immune Response to Acute Focal Cerebral Ischemia and Associated Post-stroke Immunodepression: A Focused Review.

Authors:  Bolanle M Famakin
Journal:  Aging Dis       Date:  2014-10-01       Impact factor: 6.745

Review 6.  Healthcare-Associated Infections in the Neurocritical Care Unit.

Authors:  Katharina M Busl
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-27       Impact factor: 5.081

7.  Increased infections with β-blocker use in ischemic stroke, a β2-receptor mediated process?

Authors:  Jordan B Starr; David L Tirschwell; Kyra J Becker
Journal:  Neurol Sci       Date:  2017-03-03       Impact factor: 3.307

Review 8.  Brain-immune interactions and ischemic stroke: clinical implications.

Authors:  Hooman Kamel; Costantino Iadecola
Journal:  Arch Neurol       Date:  2012-05

9.  Role of B cells and the aging brain in stroke recovery and treatment.

Authors:  E B Engler-Chiurazzi; K L Monaghan; E C K Wan; X Ren
Journal:  Geroscience       Date:  2020-08-07       Impact factor: 7.713

Review 10.  Immune interventions in stroke.

Authors:  Ying Fu; Qiang Liu; Josef Anrather; Fu-Dong Shi
Journal:  Nat Rev Neurol       Date:  2015-08-25       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.